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Purpose: This study summarizes findings from objective assessments of compliance 
(or adherence) and persistence with ocular hypotensive agents in patients with glaucoma and 
ocular hypertension.
Design: Systematic literature review.
Methods: A PubMed and reference list search was conducted across publication years 
1970–2010, using these terms and variants: “compliance,” the equivalent term “adherence,” and 
“persistence” in patients with these conditions and therapies. Summaries of selected studies were 
stratified by measurement method (electronic monitor, prescription fills review, medical chart 
review). Measures of central tendency across studies were calculated for commonly-reported 
compliance or persistence measures.
Results: Fifty-eight articles met all inclusion/exclusion criteria: measurement of compliance–
electronic monitoring (seven studies reported in 14 articles), measurement of compliance/
persistence–prescription records (36 studies in 38 articles), and measurement of persistence–
medical chart review (six studies in six articles). From electronic monitoring, most therapy-
experienced patients took medication consistently, but $20% met criteria for poor compliance. 
From prescription records, only 56% (range 37%–92%) of the days in the first therapy year could 
be dosed with the medication supply dispensed over this period. At 12 months from therapy 
start, only 31% (range 10%–68%) of new therapy users had not discontinued, and 40% (range 
14%–67%) had not discontinued or changed the initial therapy. From medical chart review, only 
67% (range 62%–78%) of patients remained persistent 12 months after starting therapy.
Conclusions: Evidence provided by this review suggests that poor compliance and persistence 
has been and remains a common problem for many glaucoma patients, and is especially prob-
lematic for patients new to therapy. The direction of empirical research should shift toward a 
greater emphasis on understanding of root causes and identification and testing of solutions 
for this problem.
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Introduction
As with many chronic insidious conditions, such as hypertension and diabetes, 
unsuccessfully controlled glaucoma typically worsens through a gradual progres-
sion, producing few symptoms until further permanent debilitation occurs, the latter 
condition being diagnosed in part upon the appearance of damage to the optic nerve 
(eg, cupping or loss of visual field). Glaucoma may be preceded by the appearance of 
ocular hypotension, an asymptomatic condition marked by elevated intraocular pres-





Without the reinforcing amelioration of symptoms 
through use of pharmacotherapy, patients with glaucoma and 
ocular hypertension may be less inclined to maintain regular 
and continued use of their ocular hypotensive therapy. The 
additional self-administration hurdle of topical eye drops 
(compared with the oral formulations commonly used in 
other conditions) may further depress the motivation of these 
patients to comply and persist with therapy.1
In a recent editorial, Quigley makes a case for why clini-
cians should seriously consider this problem:2
“If we could help patients with glaucoma take their 
drops better, it would be like doubling the effect of their 
  treatment – the equivalent of adding a second drop. This 
is true because, on average, patients with chronic medical 
conditions take from 30% to 70% of prescribed medication 
doses, and up to half discontinue medications in the first 
months of therapy.3,4 These dismal facts apply to the use of 
eye medicines as well.”5
Although one review6 found no strong evidence 
supporting an association between compliance and glaucoma 
progression, longitudinal research into this association 
remains quite limited. For ophthalmologists, the treatment 
goal remains: to provide patients with appropriate ocular 
hypotensives for their clinical and personal needs and to 
encourage compliance so that a desired level of IOP is 
reached.
Although one might consider compliance and persis-
tence problems in glaucoma to be common knowledge, 
systematic reviews are useful for providing a more objective 
and thorough summary of the weight of evidence across 
the empirical knowledge base. In a 2005 systematic review 
devoted to glaucoma non-compliance, Olthoff et al reported 
that the proportion of patients who deviated from their pre-
scribed medication regimen ranged from 5% to 80%.6 These 
authors further found that no determinants (patient factors) 
were sufficiently sensitive and specific to accurately identify 
potential non-compliers. In a recent systematic review of 
glaucoma therapy issues, which also included a section on 
compliance and persistence problems, Lu et al found that 
“[r]ates of nonadherence ranged between 23% and 60% over 
12 months … [r]ates of non-persistence ranged between 30% 
and 95% at 1 year.”7
Since the time of the focused review by Olthoff et al,6 
the number of empirical publications on this topic has 
approximately doubled (based on the number of eligible 
studies identified in the current study). The purpose of 
the current study is to update these earlier reviews6,7 on 
the measured magnitude of compliance or persistence 
problems in glaucoma (but this time limiting the scope 
to objective assessments rather than addressing the 
problematic issues related to self-reported compliance 
assessment without objective reference), to stratify find-
ings by measurement method used (ie, electronic monitor, 
prescription fills, and medical chart), since each captures 
a different aspect of compliance and persistence, and to 
summarize findings by central tendency rather than by all-
encompassing, but perhaps less-useful general ranges of 
findings. Due to the large number of eligible studies identi-
fied in the current review, additional issues examined in 
earlier reviews regarding the association between choice of 
agent and associated levels of compliance or persistence,7 
and the association of compliance and persistence with 




In a recent report, a health outcomes working group cited 
the lack of guidance regarding the terms “compliance,” 
“adherence,” and “persistence.”8 This group concluded that 
compliance and adherence are synonyms, compliance sim-
ply being the more commonly used term. Medication com-
pliance (or its synonym adherence) is thus defined as “…the 
degree or extent of conformity to the recommendations 
about day-to-day treatment by the provider with respect 
to the timing, dosage, and frequency.”8 Medication per-
sistence was further defined by this working group as 
“… the act of continuing the treatment for the prescribed 
duration. It may be defined as ‘the duration of time from 
initiation to discontinuation of therapy’.”8 Despite the 
finding of this working group for equivalence of the terms 
“compliance” and “adherence,” Osterberg and Blaschke 
state, that “[t]he word ‘adherence’ is preferred by many 
health care providers, because ‘compliance’ suggests that 
the patient is passively following the doctor’s orders and 
that the treatment plan is not based on a therapeutic alli-
ance or contract established between the patient and the 
physician.”9 However, for purpose of this review, we avoid 
interpretation of authors’ intent in usage of these terms 
(which is often unclear) but rather favor the position of 
this working group to view the term “adherence” as neither 
less derogatory nor as more preferred by patients, but as 
simply synonymous with “compliance.”8 Thus, to provide 
a standardized terminology, in the body of this review we 
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authors used the term “adherence.” However, to maintain 
a bridge of continuity with the original publication, in the 
summary tables describing each study we provide the exact 
terms as used by the original authors.
Literature search and article selection
A systematic literature review was conducted using the 
PubMed search tool to search MEDLINE and other life 
science journals (www.ncbi.nlm.nih.gov/pubmed). The fol-
lowing search terms, applied to the full PubMed database, 
were used: (compliance OR adherence OR adherent OR 
persistence OR persistency) AND (glaucoma OR ocular 
hypertension). English language studies published in journals 
over the time period 1/1/1970–12/31/2010 were included 
(search last updated 2/1/2011). Reference sections within 
articles that met inclusion and exclusion criteria, as well as 
any published literature reviews, were also considered to 
identify additional titles.
One reviewer (GR) independently screened titles. 
Abstracts of potential topic-related studies were then 
reviewed. When an abstract was not available or did not 
provide enough detail for determining inclusion, full 
text articles were retrieved. Studies that were eligible for 
inclusion for the current review included only those that 
reported original research findings for at least one objective 
assessment of compliance or persistence for patients receiv-
ing any ocular hypotensive agent. Any study that reported 
patient or physician self-assessed (subjective) measures 
of compliance or persistence was examined, but was not 
included in the current review unless one or more objec-
tive measures was also obtained and reported within the 
same study.
The following types of studies were excluded from this 
review: (1) editorials, letters, and other commentary pieces, 
(2) narrative or clinical topic reviews, (3) case studies, (4) 
studies that had required failure on previous glaucoma 
therapy as an inclusion criterion for subject selection (thus 
containing an uncontrolled bias of regression to the mean), 
(5) interventional studies (such studies would typically 
not reflect usual care for glaucoma), unless a separate pre-
interventional observation period was conducted for the 
entire patient sample (both study arms). Studies that selected 
patients who were not new to ocular hypotensive therapy 
or who were required to meet some minimum threshold 
of persistence on therapy were not excluded from this 
review. However, such selection rules could have affected 
findings and are thus separately identified by study when 
employed.
Data abstraction
The full text of included articles was reviewed. One reviewer 
(GR) reviewed each study and extracted information for 
placement in a summary table organized by objective 
estimation method, citation, design summary, endpoint(s) 
measured, patient selection/study setting, study year, and 
summarized study findings on these endpoints.
Persistence and compliance findings 
across drug cohorts
Several studies quantified persistence on therapy by using 
survival analysis methods. The primary focus of such studies 
was a comparison of the relative risk of time to therapy fail-
ure among products or classes of ocular hypotensive agents. 
Therapy failure was typically defined as discontinuation or 
change of therapy or both. Few such survival studies reported 
the proportion of patients who had failed therapy by combin-
ing all cohorts. Even among individual cohorts, few reported 
exact proportions of patients who had failed therapy at spe-
cific points in time (eg, at 180 days, 1-year, 2-year intervals) 
unless such findings were displayed as Kaplan–Meier (KM) 
or Cox Proportional Hazard Model plots.
We developed a method to summarize findings for the 
entire study sample when results were reported only by drug 
cohort or as KM or Cox survivor function plots. The propor-
tion remaining persistent at 12 months from treatment start 
was recorded for each such study (no study had a shorter 
follow-up). For those whose 12-month persistence findings 
were available only within plots rather than in table or text, 
the following method was used: for each article that was not 
already available as an electronic file, we scanned plots from 
the printed copy. For all plots, SnagIt 8.0 (www.techsmith.
com) was used to convert a full-screen magnification of the 
displayed electronic graph to a high-quality JPEG graphic 
file. Engage Digitizer 4.1 (www.digitizer.sourceforge.net), 
an open-source software package designed for plot-to-data 
conversions, was used to translate the JPEG plot line for 
each cohort to a spreadsheet of persistence values, at the 
points where the y-axis (percentage remaining persistent) 
intersected the corresponding time value immediately before, 
through and after 12 months, as shown at the x-axis. For the 
12-month time point, the mean persistence (n-weighted by 
drug cohort), and range of persistence values across all drug 
cohorts within each study were calculated and reported.
Many of the authors described the same study sample in 
two or more published articles. However, in each of these 
articles, a different analysis of that sample data was reported. 





appearing to use the same cohort have been combined within 
tables into a single group of summarized findings (ie, as a 
single “study group”). However two studies10,11 that analyzed 
a subsample from within a larger sample are considered for 
this review as new studies, and are separately described. 
Stata (Intercooled 8.0, College Station, TX) was used for 
statistical analysis.
Unless otherwise indicated, all measures of compliance or 
persistence refer to usage of the originally prescribed agent 
only. However, in two studies noted below, by   Gurwitz et al,12,13 
usage of any ocular hypotensive following the initially pre-
scribed agent was included within the compliance estimate.
Results
The last updated search of the PubMed database (2/11/2011) 
yielded 635 unique titles. This literature search and review of 
reference sections yielded 58 articles (comprising 49 study 
groups) that were deemed to have met all inclusion and 
exclusion criteria. These articles were categorized by mea-
surement method and are separately listed by study group in 
Supplementary tables 1 (electronic monitor), 2 (prescription 
fills), and 3 (chart review).
Figure 1 summarizes the count of reviewed articles by 
publication year. Few articles were published before the year 
2000. Thirty-four of the 58 articles were published between 
2005 and 2010.
Measurement of compliance – electronic 
monitoring
Electronic monitoring provides a means of monitoring com-
pliance by objectively capturing the opening and closing of 
a vial enclosure, or the vial itself, by study subjects over a 
defined follow-up period. Both the date and time for each 
instance of opening and closing are captured. The design of 
these studies is prospective; all subjects have agreed to par-
ticipate. Depending on the design of the study, subjects may, 
or may not, have been told that usage of medication was being 
monitored. Because of the precise level of detail on timely 
usage of medication over time, this method has been referred 
to as the “gold standard” for compliance measurement.14,15 
Limitations with electronic monitoring include the short 
follow-up period generally available, and the potential for 
introducing experimenter’s bias, both a consequence of the 
clinical trial-like setting of such studies. Supplementary 
table 1 lists the seven identified non-interventional study 
groups (reported in 14 articles) using electronic monitors.
Norrell, in 1979, published the earliest of all articles 
evaluated in this review, evaluating usage within a group 
of patients of a small box-like monitoring device that held 
a pilocarpine vial.16 This was followed by six articles17–22 
reporting separate analyses of the same Swedish cohort and 
a separate study that analyzed a sub-sample of this larger 
cohort, by Granstrom (in 1985).10 Kass et al (in 1986),23,24 
and Kass et al (in 1987)25 separately reported findings from 
two US cohorts using a smaller, integrated vial/monitoring 
device. Robin et al (in 2007),26 Hermann et al (in 2010),27 
and Hermann et al (in 2010)28 reported findings from separate 
cohorts in the US, Greece, and France, respectively, each of 
which also used an integrated vial/monitoring device. All 
studies appeared to examine patients who were existing users 
of ocular hypotensive therapy, and all, except Robin et al,26 
masked the purpose of the monitor from some or all subjects; 
in Hermann et al27 patients were randomly assigned to masked 
and unmasked cohorts. The latter study found no significant 
differences in among compliance endpoints between masked 
and unmasked cohorts.
Among all monitoring studies, the lowest rates of com-
pliance were found in the recent Hermann et al studies;27,28 
each evaluated brimonidine users. Over a 1-month period the 
ratios of recorded-to-intended doses across patient samples 
in the two countries examined were 62%28–64%27 for thrice-
daily users vs 72%28–73%27 for twice-daily users. Kass et al 
reported that, over a 1-month period, only 76% of prescribed 
doses were taken in a study of pilocarpine users24 vs 83% 
in a later study of timolol users.25 Norell and Granstrom 
found, over a 20-day period, that 90% of prescribed doses 
of pilocarpine appeared to be administered (only 10% were 
missed).18 Robin et al found, over a 60-day period, that 97% of 
prescribed doses of prostaglandins were administered within 
2 hours of the scheduled time.26 Despite the relatively high 
compliance rates found in the latter two studies, both found 
a substantial clustering of poor compliance behavior among 































Compliance and persistence in glaucoma
Table 1 Mean of compliance and persistence endpoints
Source Endpoint Mean  
of studiesa
SD Range Number  
of studies
Rx fills Percentage persistent at 1 year until  
discontinuation of therapy1,5,30–41
31% 17% 10%–68% 14
Rx fills Percentage persistent at 1 year until  
discontinuation or change of therapy32,36–38,40–47
40% 19% 14%–67% 12
Rx fills Medication possession at end of 1st year5,48,49 51% 7% 44%–59% 3
Rx fills Medication possession ratio or proportion  
of days covered over 1st year1,12,13,31,49,51
56% 19% 37%–92% 6
Rx fills Rate of total non-adherence (no refills  
following start of therapy in 1st year)12,13
24% 1% 23%–25% 2
Medical  
chart
Percentage persistent at 1 year until change  
(or change/discontinuation) of therapy11,61–64
67% 7% 62%–78% 5
Notes: aMean across studies for those endpoints that were reported in two or more reviewed studies (within-study means were derived by n-weighting drug cohorts if 
a total-sample mean was not available). The denominator for mean of studies estimate is the total number studies within the source category, except for two studies that 
reported findings for two separate cohorts: diagnosed glaucoma and glaucoma suspect5 and primary open-angle glaucoma and ocular hypertension.51 For these exceptions, 
both cohorts were included in both the numerator and denominator when calculating the mean of studies estimates. For Tingey et al64 persistence findings include only the 
Phase 1 cohort (those starting first-line glaucoma treatment) but exclude the Phase II cohort (those who previously failed beta blocker therapy).
Abbreviation: Rx, prescription.
subjects had intermediate (missed 10%–19% of doses) and 
20% had poor compliance (missed $ 20% of doses),22 while 
Robin et al found that 20% of subjects had poor compliance 
(. five errors over 20 days).26
Measurement of compliance and 
persistence – prescription records review
The 36 study groups (reported in 38 articles) analyzing prescrip-
tion fill records accounted for nearly two-thirds of all published 
articles in this review (Supplementary table 2). Many of these 
studies reported findings for both compliance and persistence 
endpoints. Many compared the relative persistence perfor-
mance between various drug cohorts. Across these studies, 
Table 1 summarizes findings for compliance and persistence 
among those specific endpoints used in more than one study.
Time to therapy failure using survival analysis
All studies using survival analysis were conducted retrospec-
tively with prescription fill or medical chart data. Since survival 
analysis employs censoring of subjects who are lost to, eg, fol-
low-up through health plan or other database disenrollment, or 
reaching the end of the study, this method offers the advantage 
of including subjects without the need for a minimum avail-
able follow-up period. This method tracks for the occurrence 
of a “failure” event, eg, discontinuation, or discontinuation/
change on therapy. This method is much less precise than 
electronic monitoring for identifying a sentinel deviation from 
scheduled therapy, and must rely on establishing criteria for 
defining a substantial delay or gap in refilling or re-issuing of 
a prescription, or the introduction of a new agent, to identify 
a failure event. Except in two studies described below,29,30 this 
method does not typically measure whether patients return to 
therapy once a failure event is indentified.
As shown in Table 1, 14 studies1,5,30–41 used survival analysis 
to evaluate time to therapy discontinuation from prescrip-
tion fills, all but one33 of which reported findings for patients 
who were stated to have evidence of being new to any ocular 
hypotensive therapy (ie, were assumed treatment-naïve). Across 
the 14 studies, a mean of 31% (range 10%–68%) of all patients 
had remained persistent (no discontinuation) on their initial 
ocular hypotensive at the end of 12 months from the start of 
therapy. Twelve studies used survival analysis to evaluate time 
to therapy discontinuation or change (eg, switch of initial agent 
or addition of adjunctive agent).32,36–38,40–47 Of these, all but 
three42,43,46 provided evidence that patients were treatment-naïve. 
Across the twelve studies, a mean of 40% (range 14%–67%) of 
patients remained persistent (no discontinuation or change) at 1 
year. When analysis was restricted to those six studies separately 
reporting both discontinuation and discontinuation/change 
persistence rates,32,36–38,40,41 a mean of 35% (range 19%–68%) 
had not discontinued and 26% (range 14%–55%) had not dis-
continued or changed the initially prescribed agent.
Schwartz et al29 and Zimmerman et al30 evaluated the 
subsequent disposition of patients who had discontinued 
therapy during the first observation year. Although only 10% of 
treatment-naïve patients in Zimmerman et al30 were persistent 
on therapy at year’s end, 55% of the total sample had been 
non-persistent but later restarted therapy before the end of this 
year. Only 19% of the total sample had completely discontinued 
all ocular hypotensive therapy without evidence of restarting 
any therapy at the end of this year. Schwartz et al found that, 





day 180, only 51% of these treatment-naïve patients had failed 
to restart therapy by the end of the observation year.29
Medication possession at 12 months for new therapy 
starts
Medication possession uses prescription fill records to 
assess whether a patient has a sufficient supply of the study 
drug on hand (ie, “possession”) at a given point in time, for 
instance at 6 months or 1 year after starting therapy. Although 
medication possession offers a simple method for estimating 
persistence, it does not provide a summary estimate of usage 
of the study drug for the period prior to the time point at which 
possession is assessed. For the three studies5,48,49 that reported 
medication possession at 12 months (Table 1), a mean of 51% 
(range 44%–59%) of all patients had a supply of the initially 
prescribed agent on hand at year’s end. Separately, Wilensky 
et al50 found, for patients who had successfully remained on 
therapy for at least 3 months, that 69% later had possession 
at 1 year. Each of the medication possession studies evaluated 
only patients who were new to therapy.
Proportion of days covered (PDC) and medication 
possession ratio (MPR)
The PDC and MPR both capture approximate days over a given 
period for which patients have sufficient days supply to admin-
ister therapy. Both the MPR and PDC use the same numerator, 
the sum of days supply of all prescription fills over the period. 
However, while the MPR uses the number of elapsed days 
from the initial fill to the final fill of a prescription over the 
follow-up period, the PDC uses elapsed days from initial fill 
until a given point in time (eg, 6 months, 12 months) after the 
initial fill as the denominator. For the six studies that reported 
MPR or PDC rates during the 12 months after therapy start 
(five of which evaluated treatment-naïve patients),1,12,13,31,49,51 
56% (range 37%–92%) of the days in the first therapy year 
could be dosed with the total days supply of prescriptions 
dispensed over this period. Separately,   Friedman et al found, 
for treatment-naïve patients, a mean MPR of 64% across a 
mean follow-up of 22 months.48   Wilensky et al found a PDC 
of 76% for patients over the first year who were treatment-
naïve but who had been continuously persistent on therapy for 
90 days following therapy start.50 Djafari et al found that 72% 
of patients had a PDC ratio of $75% over a 2-year period, for 
a mix of patients new and not new to therapy.52
Other measures using prescription fills
Lee et al found that 89%, 71%, and 22% of patients (likely 
existing users) had at least one significant gap in therapy 
during a 12-month follow-up period when evaluating allowed 
gaps of 45, 60, and 120 days, respectively.53 Friedman et al 
found that 90% of treatment-naïve users experienced at least 
one significant gap over an average 22-month follow-up 
period; further, 20% of all patients discontinued all ocular 
hypotensives, with no evidence of adding, switching, or 
restarting agents.48 Another study by Friedman et al reported 
associations of MPR with patient-reported factors in a subset 
of patients from this earlier study but did not report MPR 
estimates.54 Higginbotham et al reported that only 30% of 
existing or new therapy users had not changed or discontinued 
any ocular hypotensive agent during the 1-year period after 
audit of a retail pharmacy database.55 Gurwitz et al also 
reported that a mean of 24% of patients failed to receive 
a refill or fill for any ocular hypotensive agent (original or 
new) in the year following start of therapy in treatment-
naïve patients (Table 1).12,13 Muir et al reported that patients 
enrolled in a study of factors related to compliance had only 
refilled their ocular hypotensive a mean of 2.5 times during 
the 6 months prior to being interviewed.56,57 Robin et al found 
in a study of patients who were persistent with latanoprost in 
the year prior to receiving at least two fills of an adjunctive 
agent that the mean interval between refills for latanoprost 
increased from 40 days prior to introduction of the adjunctive 
agent to 47 days afterwards.14 Rotchford and Murphy reported 
that 51% of patients (existing users) for whom dispensing 
information was available did not have sufficient timolol to 
medicate as prescribed over the observed treatment year.58 
Using a combination of prescription records and patient 
self-reports of non-adherence to define refill non-adherence, 
Stryker et al found that 67% of existing therapy users were 
classified as non-adherent over a non-defined observation 
  period.59 Yousuf and Jones found that, even within an in-
patient hospital setting, mean adherence rates with prescribed 
ocular hypotensive medication was only 67%.60
Measurement of compliance and 
persistence – medical chart review
As shown in Supplementary table 3, six studies11,61–65 
analyzed medical chart data to estimate rates of persistence 
among patients receiving ocular hypotensives. All but one65 
analyzed persistence on therapy using survival analysis (four 
in treatment-naïve patients), evaluating either time to therapy 
change, or time to therapy discontinuation or change. Since we 
considered it unlikely that ophthalmologists would have dis-
continued therapy without replacement with some other ocular 
hypotensive agent, results for the five studies using either 
of these two persistence endpoints are combined in Table 1. 
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Many methodological issues found in this review appear 
to be independent of measurement method. For instance, 
many studies selected only patients who were treatment-naïve. 
Others evaluated existing ocular hypotensive users or a mix 
of the two groups. This is an important consideration for 
interpretation of findings, particularly since differences in 
compliance and persistence could be expected across these 
selected groups. Patients who are existing therapy users are by 
definition more experienced and are largely therapy survivors, 
having refilled at least one prescription. These users would be 
expected to be more likely to properly consume their initial 
therapy when compared those just starting therapy.
Despite design limitations among methods, much has 
been learned from the body of empirical research evaluated in 
this review. By comparing every scheduled to actual admin-
istered dose, the electronic monitor studies provide uniquely 
precise estimates of daily medication-taking behavior by 
established ocular hypotensive users. Thus, of the most com-
monly used glaucoma agents today, the prostaglandins and 
beta blockers, findings from the electronic monitor studies 
suggest that compliance behavior remains a problem for a 
substantial proportion in existing users, perhaps one in five26 
to one in four.25 These studies also suggest a general trend 
toward greater compliance with fewer required doses per 
day, clearly established in Hermann et al,27,28 and suggested 
with the improved compliance observed in the timolol and 
prostaglandin studies compared with the thrice-daily regi-
mens of brimonidine and pilocarpine.
The greatest strength of survival analysis-based persistence 
studies from prescription records is the sheer volume of evidence 
that most patients (perhaps two in every three) who are new to 
ocular hypotensive therapy will have a substantial gap in refilling 
their initially prescribed agent in the first year of therapy. Analy-
sis of persistence data from medical charts suggests that perhaps 
one of every three patients would have undergone a change in 
agents, either as a switch or addition of an adjunctive agent. 
Accounting for this difference would yield a net count of one 
in three patients who had started therapy but had discontinued 
(without change in agents) by the end of the first therapy year. 
What became of therapy for these patients? Zimmerman et al30 
and Schwartz et al29 suggest that approximately half of these 
would have resumed their originally prescribed therapy after this 
significant therapy failure or gap. A limitation of survival studies 
is that little is known about continued persistence on therapy for 
those patients who are either switched to a new agent or who 
return to their initial agent after a substantial gap.
Like the survival analysis, medication possession assesses 
persistence on therapy at a given point in time (though it lacks 
of patients were shown by chart to have remained persistent 
with their starting therapy at the end of the first therapy year. 
Persistence rates in the sixth study65 could not be evaluated.
Discussion
As described, the number of studies employing objective 
assessments of compliance and persistence in glaucoma phar-
macotherapy is substantial and has recently accelerated, more 
than doubling over the past 6 years. Interpretation of findings 
across these many studies is made somewhat difficult by the 
heterogeneity of methods for measuring compliance and per-
sistence endpoints, and in the varied patient selection criteria 
used in the studies reviewed. These multiple methods, when 
viewed in total, yield a range of perspectives for understanding 
compliance and persistence problems. However each must be 
interpreted with an understanding of its inherent limitations.
Although the electronic monitor likely comes closest to 
modeling actual medication use of the established ocular 
hypotensive user, such studies to date have yielded little 
understanding regarding users who are new to therapy. 
The short follow-up periods and clinical-trial-like designs 
somewhat limit attempts to generalize such findings to long-
term use in naturalistic settings. The lack of uniformity across 
studies in the specific endpoints used to estimate compliance 
from monitoring data (as shown in Supplementary table 1) 
perhaps more strongly limits attempts to compare findings 
across these studies.
While a review of prescription fill records offers the 
potential to greatly extend the observation period, describe 
actual drug use in natural settings, and employ standardized 
compliance and persistence measures, many methodologi-
cal questions are left unanswered. For instance, does the 
days supply reported on the prescription fill record reflect 
the actual coverage required given what is not revealed: the 
patient’s ability to avoid wastage, whether a patient treats one 
or both eyes, the actual number of drops available in a given 
vial, and the effect of drug samples on these estimates?
The medical chart comes closest to what is available to 
the ophthalmologist as a practical tool for monitoring and 
perhaps correcting persistence problems with therapy, but 
this too has limitations. Although the prescribing physician 
should be aware of changes to therapy since he/she likely 
authorizes them, little is revealed from the chart whether a 
patient is compliant and persistent on a prescribed ocular 
hypotensive unless the patient so informs the physician or 
fails to request timely refills. Further, once a patient is lost to 
medical follow-up for failing to reschedule visits, all remain-





consideration of patients who are lost to follow-up). For new 
ocular hypotensive users, only half will have an apparent 
supply of the initially prescribed agent on hand at the end 
of the first therapy year. This improves considerably for 
“therapy survivors” who achieve initial persistence through 
first 90 days (two-thirds of these have possession at year’s 
end). Further, many patients, perhaps one in four, appear to 
simply fail to refill for any ocular hypotensive agent even 
once after starting therapy.
Although both PDC and MPR are unable to measure 
deviations from scheduled doses, they do offer a simple and 
approximate measure of days of therapy coverage or drug 
availability in a naturalistic setting. The low combined PDC/
MPR value of 56% for the five studies that reported year-end 
values appears equally poor compared with the MPR of 64% 
reported in the recent large-scale study of Friedman et al 
across an average follow-up of 22 months.48 These findings 
further suggest that a failure to refill or sporadic refilling of 
ocular hypotensives is common among patients.
Unlike evidence from electronic monitoring studies of 
compliance, persistence with ocular hypotensive therapy does 
not appear to be improving with the increased availability of 
once-daily dosing regimens. In Friedman et al’s analysis of 
claims data over the period 1999–2005, a time when once-
daily prostaglandins or beta blockers were available and 
heavily prescribed, few patients over the 22-month follow-up 
did not have at least one substantial gap in refilling; 20% 
discontinued filling of ocular hypotensives altogether.48
Summary and recommendations
Despite the greater attention devoted to this issue in recent 
years, empirical evidence provided in this review suggests 
that poor compliance remains common for many glaucoma 
patients who are existing ocular hypotensive users. Both 
compliance and persistence remain problems for those who 
are new to such therapy.
For those new to therapy, active engagement with the 
patient by the ophthalmologist, physician assistant, nurse, or 
pharmacist is especially important in the first treatment year. 
Assessment should include discussion of compliance and per-
sistence behavior, and eliciting of patient-perceived problems 
such as tolerability, forgetting doses, or the taking of drug 
holidays. Also, some evidence suggests that encouraging 
the patient to remain compliant with the scheduling of visits 
may help medication compliance. Both Gurwitz et al13 and 
Jayawant et al33 found that patients who had a higher count of 
ophthalmologist visits in the first year also had higher rates of 
ocular hypotensive compliance and persistence, respectively. 
Quigley et al found that missing an ophthalmology visit was 
associated with lower compliance with therapy.66
For existing therapy users, who are more experienced, 
often using adjunctive therapy to control their glaucoma, 
important considerations, besides missing scheduled doses, 
are dyscompliance concerns (wrong or unsuccessful use of 
eyedrops).27 In one study 44% of patients reported regularly 
missing the eye when applying drops.67 Another study found 
that less than one-third of observed instillations in existing 
users were performed successfully, with 17%–25% of patients 
unable to place a drop in their eye.68 Several of the electronic 
monitoring studies in this review found evidence pointing to 
dyscompliance. In Kass et al the weight of the pilocarpine 
vial utilized during the study was only weakly (r = 0.18) cor-
related with therapy compliance, which suggests that greater 
drug consumption may not be a good predictor of appropriate 
drug use.24 Hermann et al found that some patients required up 
to 3.7 drops per scheduled dose per eye, implying the empty-
ing of a full vial in as little as a week.28 Robin et al found, in 
subjects using beta-blockers as adjunctive therapy, that 25% 
of the intervals between beta blocker doses were 10 hours or 
lower (suggesting a potential safety issue).26
Gray et al, in their recent Cochrane review, examined 
randomized interventions to improve adherence to ocular 
hypotensive therapy.69 Only eight eligible randomized 
intervention studies published until the review year 2009 
were deemed as evaluable.69 These authors concluded that 
simplified dosing regimens, reminder devices, education, 
and individualized care planning showed improvements 
in adherence rates. Adequately controlled and designed 
interventions that may be especially worthwhile to pursue 
would include: structured but interactive patient educational 
programs, strategies to improve physician communication, 
and the integration of drug with compliance device. Ocular 
hypotensive agents may have the highest potential for effec-
tiveness and lowest levels of adverse effects, when delivered 
with dosing aids and adherence devices (see Kahook70).
Although more empirical studies to identify the scope of 
compliance and persistence problems might help track whether 
progress is being made, there is little need for further objective 
assessment in the near-term to confirm that such problems con-
tinue to exist. Building upon a legacy of more than 40 years of 
subjective and objective assessments, the direction of empirical 
compliance and persistence research in glaucoma should rap-
idly shift toward solutions: (1) performing rigorous and quan-
tifiable assessments of likely root causes of non-compliance 
and non-persistence, to identify areas for intervention,   




Compliance and persistence in glaucoma
tools to monitor and predict non-compliance, (3) evaluating 
promising compliance-improvement interventions with strong 
study designs to compensate for the limited randomized-trial 
research to date, and (4) further expanding the eight clinical 
recommendations proposed by Olthoff et al6 into a formalized 
set of guidelines for the recognition and treatment of patients 
who are potentially non-compliant or non-persistent.
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.Patient Preference and Adherence
Publish your work in this journal
Submit your manuscript here: http://www.dovepress.com/patient-preference-and-adherence-journal
Patient Preference and Adherence is an international, peer-reviewed, 
open access journal focusing on the growing importance of patient 
preference and adherence throughout the therapeutic continuum. Patient 
satisfaction, acceptability, quality of life, compliance, persistence and 
their role in developing new therapeutic modalities and compounds to 
optimize clinical outcomes for existing disease states are major areas of 
interest. This journal has been accepted for indexing on PubMed Central. 
The manuscript management system is completely online and includes a 
very quick and fair peer-review system. Visit http://www.dovepress.com/ 
testimonials.php to read real quotes from published authors.





Compliance and persistence in glaucoma